# Portal Innovations

> Portal Innovations is a VC fund in Chicago backing Biotechnology and Medical. See 15 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Chicago, United States
- Total investments: 15
- Last investment: Jun 2026
- Lead investor: 13%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/portal-innovations-llc/
- X (Twitter): https://twitter.com/portalinno?lang=en
- Website: https://www.portalinnovations.com/
- Facebook: https://www.facebook.com/pages/category/Product-Service/Portal-Innovations-107648627709007/

Portal Innovations is a VC fund in Chicago focused on Biotechnology and Medical. Portal Innovations invests in therapeutics, med tech, and bioinformatics startups with strong leadership teams.

## Contacts

5 contacts available for Portal Innovations. Shizune tracks 1 team members at Portal Innovations. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/portal-innovations?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 9 | 60% |
| Medical | 8 | 53% |
| Health Care | 6 | 40% |
| Therapeutics | 3 | 20% |
| Wearables | 2 | 13% |

20 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 8 | 53% |
| Seed | 6 | 40% |
| Pre-Seed | 1 | 7% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| John L. Flavin | Founder & CEO | 3 | https://shizune.co/investors/profile/john-l-flavin |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| SyntaxBio | SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention. | $14.4M | Series A | Jun 21, 2026 |  |
| Syntis Bio | Syntis Bio operates as a late-stage preclinical company intended to develop a new class of therapy. The company's drug uses novel formulations for oral therapies that target specific tissues, enabling users to increase bioavailability. | $33M | Series A | Jul 01, 2025 |  |
| Vincere Biosciences | Vincere Biosciences is a JLABS incubator company whose mission is to develop drugs to halt the progression of Parkinson's disease (PD). | $5M | Series A | Apr 01, 2025 |  |
| Synaptrix | Synaptrix is committed to offering free of drugs, lasting alternatives for postoperative pain treatment using NOVABLOC. | $10M | Series A | Nov 15, 2024 |  |
| CrossBridge Bio | CrossBridge Bio operates as a biotechnology company, innovates ADC therapeutics through stable dual linker payload technology. | $10M | Seed | Nov 04, 2024 |  |
| March Biosciences | March Biosciences is a clinical-stage cell therapy company that focuses on developing CAR-T cell strategies to address hematological cancers. | $28.4M | Series A | Oct 23, 2024 |  |
| SyntaxBio | SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention. |  | Seed | Sep 17, 2024 |  |
| Moonlight Therapeutics | Moonlight Therapeutics is focused on developing safe, effective, and patient-friendly treatments for people suffering from food allergies. | $2.4M | Seed | Aug 15, 2024 |  |
| Alnair Therapeutics | Alnair Therapeutics is a preclinical stage precision oncology platform focusing on developing innovative approaches to treat difficult-to-treat malignancies. It has created a first-of-its-kind drug delivery technology that uses the unique features of cancer metabolism to improve drug targeting and penetration directly into cancer cells, henceenhancing patient treatment outcomes. | $1M | Pre-Seed | Jun 30, 2023 |  |
| Dimension Inx | Dimension Inx focuses on creating advanced biomaterials and 3D-printed implants that fundamentally change human disease and debilitation. It specializes in the fields of additive manufacturing, 3D-printing, biomaterials, and manufacturing. It was founded in 2017 and headquartered in Chicago, Illinois. | $12M | Series A | Feb 01, 2023 |  |

10 of 15 investments shown.

## Co-investors
- [Mansueto Investments](https://shizune.co/investors/profile/mansueto-investments) — VC Fund, 3 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 2 deals together
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund, 2 deals together
- [Astellas Venture Management](https://shizune.co/investors/profile/astellas-venture-management) — VC Fund, 2 deals together
- [Bold Capital Partners](https://shizune.co/investors/profile/bold-capital) — VC Fund, 2 deals together
- [Colorcon Ventures](https://shizune.co/investors/profile/colorcon-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Portal Innovations invest in?

Portal Innovations invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Seed stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Portal Innovations?

Public channels for Portal Innovations include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Portal Innovations?

The team at Portal Innovations includes John L. Flavin (Founder & CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co